GSK’s Krintafel (tafenoquine) Receives FDA Approval Preventing the Relapse of P.vivax Malaria

 GSK’s Krintafel (tafenoquine) Receives FDA Approval Preventing the Relapse of P.vivax Malaria

GSK Signs a Worldwide Development & Commercialization Collaboration with Merck KGaA, for $4.2B

Shots:

  • The approval is based on Detective Part 1 & Part 2 (TAF112582) and Gather (TAF116564) studies results assessing Krintafel (tafenoquine, 300mg) in 800 patients with relapse P.vivax malaria
  • The study demonstrated with safety & effective results in global clinical development P.vivax relapse program built in collaboration with Medicines for Malaria Venture(MMV)
  • Krintafel (tafenoquine, 300mg) is a novel single dose 8-aminoquinoline used as anti-relapse of P.vivax malaria, active against all stages of P.vivax lifecycle with its awaited TGA, Australia. Additionally, GSK received priority review voucher from FDA for Krintafel’s approval

Click here to read full press release/ article | Ref: GSK | Image: The Irish Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post